Immunometabolic rewiring in long COVID patients with chronic headache

Almost 20% of patients with COVID-19 experience long-term effects, known as post-COVID condition or long COVID. Among many lingering neurologic symptoms, chronic headache is the most common. Despite this health concern, the etiology of long COVID headache is still not well characterized. Here, we present a longitudinal multi-omics analysis of blood leukocyte transcriptomics, plasma proteomics and metabolomics of long COVID patients with chronic headache. Long COVID patients experienced a state of hyper-inflammation prior to chronic headache onset and maintained persistent inflammatory activation throughout the progression of chronic headache. Metabolomic analysis also revealed augmented arginine and lipid metabolisms, skewing towards a nitric oxide-based pro-inflammation. Furthermore, metabolisms of neurotransmitters including serotonin, dopamine, glutamate, and GABA were markedly dysregulated during the progression of long COVID headache. Overall, these findings illustrate the immuno-metabolomics landscape of long COVID patients with chronic headache, which may provide insights to potential therapeutic interventions.

[1]  G. Gkoutos,et al.  Symptoms and risk factors for long COVID in non-hospitalized adults , 2022, Nature Medicine.

[2]  J. Switzer,et al.  Neuropsychiatric sequelae of long COVID-19: Pilot results from the COVID-19 neurological and molecular prospective cohort study in Georgia, USA , 2022, Brain, Behavior, & Immunity - Health.

[3]  A. Prince,et al.  Immunometabolic crosstalk during bacterial infection , 2022, Nature Microbiology.

[4]  Thomas E. Nichols,et al.  SARS-CoV-2 is associated with changes in brain structure in UK Biobank , 2022, Nature.

[5]  D. García‐Azorín,et al.  Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients , 2022, Cephalalgia : an international journal of headache.

[6]  Inyoul Y. Lee,et al.  Multiple early factors anticipate post-acute COVID-19 sequelae , 2022, Cell.

[7]  Á. G. Guerrero Peral,et al.  Frequency and phenotype of headache in covid-19: a study of 2194 patients , 2021, Scientific Reports.

[8]  I. Cobos,et al.  Dysregulation of brain and choroid plexus cell types in severe COVID-19 , 2021, Nature.

[9]  Q. Wells,et al.  Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection , 2021, JAMA network open.

[10]  Shao Li,et al.  Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications , 2021, Nature communications.

[11]  J. Álvarez-Sabín,et al.  Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution , 2020, Cephalalgia : an international journal of headache.

[12]  Á. Planchuelo-Gómez,et al.  Phenotypic characterization of acute headache attributed to SARS-CoV-2: An ICHD-3 validation study on 106 hospitalized patients , 2020, Cephalalgia : an international journal of headache.

[13]  A. Dahshan,et al.  Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study , 2020, Cephalalgia : an international journal of headache.

[14]  Mark M. Davis,et al.  Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19 , 2020, Cell.

[15]  T. Horng,et al.  Lipid Metabolism in Regulation of Macrophage Functions. , 2020, Trends in cell biology.

[16]  Seoyon Yang,et al.  Association between Chronic Pain and Alterations in the Mesolimbic Dopaminergic System , 2020, Brain sciences.

[17]  J. Arenillas,et al.  Frequency and Type of Red Flags in Patients With Covid‐19 and Headache: A Series of 104 Hospitalized Patients , 2020, Headache.

[18]  I. Sereti,et al.  Immunometabolism and HIV-1 pathogenesis: food for thought , 2020, Nature Reviews Immunology.

[19]  Maria Thom,et al.  The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings , 2020, Brain : a journal of neurology.

[20]  E. Hod,et al.  COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. , 2020, JCI insight.

[21]  Lara Jehi,et al.  Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing , 2020, Chest.

[22]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[23]  M. Mittelbrunn,et al.  Glycolysis – a key player in the inflammatory response , 2020, The FEBS journal.

[24]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[25]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[26]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[27]  A. Criollo,et al.  New Insights on the Role of Lipid Metabolism in the Metabolic Reprogramming of Macrophages , 2020, Frontiers in Immunology.

[28]  H. Tilg,et al.  The intestinal microbiota fuelling metabolic inflammation , 2019, Nature Reviews Immunology.

[29]  L. Edvinsson,et al.  Does inflammation have a role in migraine? , 2019, Nature Reviews Neurology.

[30]  G. Deuschl,et al.  Neuroinflammation — a common thread in neurological disorders , 2019, Nature Reviews Neurology.

[31]  A. Leon,et al.  The role of neurotransmitters and neuromodulators in the pathogenesis of cluster headache: a review , 2019, Neurological Sciences.

[32]  W. Liu,et al.  Arginine deficiency is involved in thrombocytopenia and immunosuppression in severe fever with thrombocytopenia syndrome , 2018, Science Translational Medicine.

[33]  A. Pradhan,et al.  Targeted Nitric Oxide Synthase Inhibitors for Migraine , 2018, Neurotherapeutics.

[34]  L. O’Neill,et al.  Macrophage Immunometabolism: Where Are We (Going)? , 2017, Trends in immunology.

[35]  Frank Buttgereit,et al.  Metabolic regulation of inflammation , 2017, Nature Reviews Rheumatology.

[36]  Giuseppe Di Giovanni,et al.  Expanding the repertoire of L-DOPA’s actions: A comprehensive review of its functional neurochemistry , 2017, Progress in Neurobiology.

[37]  Philip R Holland,et al.  Pathophysiology of Migraine: A Disorder of Sensory Processing. , 2017, Physiological reviews.

[38]  Meric Erikci Ertunc,et al.  Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment , 2016, Journal of Lipid Research.

[39]  J. Rathmell,et al.  A guide to immunometabolism for immunologists , 2016, Nature Reviews Immunology.

[40]  Johannes Graumann,et al.  readat: An R package for reading and working with SomaLogic ADAT files , 2016, BMC Bioinformatics.

[41]  D. Colavito,et al.  Biochemistry of primary headaches: role of tyrosine and tryptophan metabolism , 2015, Neurological Sciences.

[42]  I. Müller,et al.  Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages , 2014, Front. Immunol..

[43]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[44]  A. Schousboe,et al.  Glutamate metabolism in the brain focusing on astrocytes. , 2014, Advances in neurobiology.

[45]  S. Kang,et al.  Sphingolipid Metabolism and Obesity-Induced Inflammation , 2013, Front. Endocrinol..

[46]  Rachel Ostroff,et al.  Life's simple measures: unlocking the proteome. , 2012, Journal of molecular biology.

[47]  G. Dussor,et al.  Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6) , 2012, Molecular pain.

[48]  P. Barberger‐Gateau,et al.  Chronic Low-Grade Inflammation in Elderly Persons Is Associated with Altered Tryptophan and Tyrosine Metabolism: Role in Neuropsychiatric Symptoms , 2011, Biological Psychiatry.

[49]  Eoin Fahy,et al.  A Mouse Macrophage Lipidome*♦ , 2010, The Journal of Biological Chemistry.

[50]  A. Ghasemi,et al.  Reference values for serum nitric oxide metabolites in an adult population. , 2010, Clinical biochemistry.

[51]  Jullie W Pan,et al.  OCCIPITAL LEVELS OF GABA ARE RELATED TO SEVERE HEADACHES IN MIGRAINE , 2008, Neurology.

[52]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[53]  W. Wilkinson,et al.  Serum, urinary, and salivary nitric oxide in rheumatoid arthritis: complexities of interpreting nitric oxide measures , 2006, Arthritis research & therapy.

[54]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[55]  R. Böger.  Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. , 2004, The Journal of nutrition.

[56]  李生花,et al.  5—HT1,5—HT2,5—HT3受体激动剂对离体蟾蜍心脏活动的影响 , 1997 .

[57]  J. Castillo,et al.  Platelet-Rich Plasma Serotonin Levels in Tension-Type Headache and Depression , 1993, Cephalalgia : an international journal of headache.

[58]  H. Kowa,et al.  Platelet Gamma‐Aminobutyric Acid Levels in Migraine and Tension‐Type Headache , 1992, Headache.

[59]  K. Welch,et al.  Cerebrospinal fluid gamma aminobutyric acid levels in migraine. , 1975, British medical journal.